[go: up one dir, main page]

MA33717B1 - Immunoconjugués ciblés - Google Patents

Immunoconjugués ciblés

Info

Publication number
MA33717B1
MA33717B1 MA34588A MA34588A MA33717B1 MA 33717 B1 MA33717 B1 MA 33717B1 MA 34588 A MA34588 A MA 34588A MA 34588 A MA34588 A MA 34588A MA 33717 B1 MA33717 B1 MA 33717B1
Authority
MA
Morocco
Prior art keywords
immunoconjugates
relates
present
nucleic acid
methods
Prior art date
Application number
MA34588A
Other languages
English (en)
Inventor
Ralf Hosse
Ekkehard Moessner
Michela Silacci-Melkko
Pablo Umana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33717(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33717B1 publication Critical patent/MA33717B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des immunoconjugués. Selon des modes de réalisation particuliers, la présente invention porte sur des immunoconjugués comprenant au moins un fragment effecteur monocaténaire et deux fragments de liaison à l'antigène ou plus. De plus, la présente invention concerne des molécules d'acides nucléiques codant pour lesdits immunoconjugués, des vecteurs et des cellules hôtes comprenant lesdites molécules d'acides nucléiques. L'invention concerne également des procédés de production des immunoconjugués de l'invention et des procédés d'utilisation des immunoconjugués dans le traitement de maladies.
MA34588A 2009-08-17 2012-01-30 Immunoconjugués ciblés MA33717B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23458409P 2009-08-17 2009-08-17
EP10162410 2010-05-10
PCT/EP2010/061810 WO2011020783A2 (fr) 2009-08-17 2010-08-13 Immunoconjugués ciblés

Publications (1)

Publication Number Publication Date
MA33717B1 true MA33717B1 (fr) 2012-11-01

Family

ID=43033282

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34588A MA33717B1 (fr) 2009-08-17 2012-01-30 Immunoconjugués ciblés

Country Status (21)

Country Link
US (1) US8945571B2 (fr)
EP (1) EP2467165B1 (fr)
JP (1) JP5764127B2 (fr)
KR (2) KR101588598B1 (fr)
CN (1) CN102573922B (fr)
AR (1) AR077879A1 (fr)
AU (1) AU2010285071A1 (fr)
CA (1) CA2769619C (fr)
CO (1) CO6430436A2 (fr)
CR (1) CR20120042A (fr)
EC (1) ECSP12011685A (fr)
ES (1) ES2534085T3 (fr)
IL (1) IL217844A0 (fr)
MA (1) MA33717B1 (fr)
MX (1) MX2012002014A (fr)
PE (1) PE20120630A1 (fr)
RU (1) RU2583876C2 (fr)
SG (1) SG178443A1 (fr)
TW (1) TW201119672A (fr)
WO (1) WO2011020783A2 (fr)
ZA (1) ZA201200767B (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
WO2011040973A2 (fr) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci
AU2015213405B2 (en) * 2010-08-13 2017-08-03 Roche Glycart Ag Anti-FAP antibodies and methods of use
JP5841149B2 (ja) * 2010-08-13 2016-01-13 ロシュ グリクアート アーゲー 抗テネイシンｃａ２抗体及び使用の方法
MA34519B1 (fr) * 2010-08-13 2013-09-02 Roche Glycart Ag Anticorps anti-fap et procédés d'utilisation
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
AU2012314860B2 (en) * 2011-09-26 2017-02-23 Philogen S.P.A. Immunocytokine combination therapy
CA2861927C (fr) 2012-01-20 2021-01-26 Vib Vzw Cytokines en faisceau a helices alpha mutantes a cible specifique
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
NZ702241A (en) * 2012-08-07 2018-04-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
AU2013301656A1 (en) 2012-08-08 2015-01-15 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
JP2015525792A (ja) 2012-08-09 2015-09-07 ロシュ グリクアート アクチェンゲゼルシャフト Ａｓｇｐｒ抗体およびその使用
WO2014043523A1 (fr) * 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014172448A2 (fr) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Anticorps diriges contre le recepteur d'activine de type ii (actrii)
EP3299466B1 (fr) 2013-07-18 2019-09-11 Vib Vzw Fusokines comprenant des cytokines avec une affinité de liaison au recepteur fortement réduite
AU2014292355B2 (en) 2013-07-19 2019-08-01 Centre Hospitalier Regional Universitaire De Montpellier Targeting of cytokine antagonists
CA2918363C (fr) 2013-07-19 2021-12-14 Centre Hospitalier Regional Universitaire De Montpellier Membres modifies et cibles de la famille du tnf
DK3022226T3 (en) * 2013-07-19 2019-03-25 Vib Vzw TARGETED MODIFIED IL-1 FAMILY MEMBERS
CA2923829A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Therapeutique ciblee
WO2015066053A2 (fr) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
WO2015116774A1 (fr) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Agents thérapeutiques cibles
EP3129064B1 (fr) * 2014-03-03 2020-01-01 Madrigal Pharmaceuticals, Inc. Thérapies ciblées
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015143004A1 (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp. Agents thérapeutiques cibles
EP3139955B1 (fr) 2014-04-30 2024-03-20 President and Fellows of Harvard College Protéines de fusion pour le traitement du cancer et procédés associés
PL3489256T3 (pl) 2014-11-14 2021-08-23 F. Hoffmann-La Roche Ag Cząsteczki wiążące antygen zawierające trimer liganda z rodziny TNF
GB201500875D0 (en) * 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
JP7028643B2 (ja) * 2015-02-13 2022-03-02 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ 膜を破壊しないｐ５３活性化ステープルペプチド
EP3973980A1 (fr) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN115594765A (zh) * 2015-10-02 2023-01-13 豪夫迈·罗氏有限公司（Ch） 对共刺激性tnf受体特异性的双特异性抗体
EP3371311B1 (fr) 2015-11-06 2021-07-21 Orionis Biosciences BV Protéines chimères bifonctionnelles et leurs utilisations
BR112018010937A2 (pt) 2015-12-04 2018-12-04 Novartis Ag composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
DK3411065T3 (da) 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3426278B1 (fr) 2016-03-07 2024-01-03 Vib Vzw Anticorps à domaine unique ciblant cd20
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3471754A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anticorps anti-pd-l1
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
KR20190092371A (ko) * 2016-09-21 2019-08-07 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 섬유아세포 활성화 단백질을 표적화하는 최적화된 합성 컨센서스 면역원성 조성물
WO2018073680A1 (fr) 2016-10-17 2018-04-26 Pfizer Inc. Anticorps anti-edb et conjugués anticorps-médicament
CA3040802A1 (fr) 2016-10-24 2018-05-03 Orionis Biosciences Nv Interferon gamma mutant cible et procedes d'utilisation associes
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
IL266827B2 (en) 2016-11-28 2025-04-01 Chugai Pharmaceutical Co Ltd Ligand binding molecule with tunable ligand binding activity, its fusion protein with a ligand, pharmaceutical compositions containing them, and method for their production
CN108250302A (zh) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
CN110573172A (zh) * 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
EP3580230A1 (fr) 2017-02-07 2019-12-18 VIB vzw Protéines chimères bispécifiques ciblées par des cellules immunitaires, et utilisations associées
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CN117003887A (zh) 2017-04-03 2023-11-07 豪夫迈·罗氏有限公司 抗pd-1抗体与突变体il-2或与il-15的免疫缀合物
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN110799194A (zh) 2017-06-20 2020-02-14 马德里加尔制药公司 包含靶向治疗剂的联合疗法
AU2018289339A1 (en) 2017-06-20 2020-01-02 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PE20250757A1 (es) 2017-08-03 2025-03-13 Amgen Inc Muteinas de interleucina 21 y metodos de tratamiento
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
TWI818934B (zh) 2017-11-28 2023-10-21 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
SG11202004897XA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Polypeptide including antigen-binding domain and carrying section
EP3737692A4 (fr) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Constructions de liaison à la calréticuline et lymphocytes t modifiés pour le traitement de maladies
KR20200110358A (ko) 2018-01-12 2020-09-23 암젠 인크 항-pd-1 항체 및 치료 방법
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
BR112020023299A2 (pt) * 2018-05-16 2021-02-02 Dragonfly Therapeutics, Inc. proteína de ligação nkg2d, cd16 e uma proteína de ativação de fibroblastos
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
CN112513276B (zh) * 2018-07-30 2024-03-15 张晋宇 蛋白质异二聚体及其用途
CA3108795A1 (fr) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Proteines chimeres ciblees sur sirp1a et leurs utilisations
US12098177B2 (en) * 2018-09-07 2024-09-24 Nantbio, Inc. Targeted IL-12 treatments and methods to stimulate haNK and NK92mi cells
JP7630426B2 (ja) 2018-10-23 2025-02-17 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体ｆｃ融合タンパク質
EP3890773A4 (fr) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. Modulation de lignées de cellules dendritiques
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
JP7773371B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド Ｃｌｅｃ９ａベースキメラタンパク質複合体
CN113874390A (zh) * 2019-05-24 2021-12-31 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
EP3980051A4 (fr) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. Fusions de polypeptides d'interleukine-2 mutants avec des molécules de liaison à l'antigène pour moduler la fonction de cellules immunitaires
WO2021001289A1 (fr) 2019-07-02 2021-01-07 F. Hoffmann-La Roche Ag Immunoconjugués comprenant une interleukine-2 mutante et un anticorps anti-cd8
EP4013783A1 (fr) 2019-08-15 2022-06-22 Janssen Biotech, Inc. Matériaux et procédés pour des fragments variables à chaîne unique améliorés
CA3163358A1 (fr) 2019-12-03 2021-06-10 Evotec International Gmbh Proteines de liaison a l'antigene associees a l'interferon et leurs utilisations
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
WO2021138474A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
IL294451A (en) 2020-04-15 2022-09-01 Hoffmann La Roche immune conjugates
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
US20230295327A1 (en) * 2020-08-11 2023-09-21 Kanaph Therapeutics Inc. Fusion protein comprising il-12 and anti-cd20 antibody and use thereof
CN116635403A (zh) 2020-12-04 2023-08-22 豪夫迈·罗氏有限公司 pH依赖性突变型白细胞介素-2多肽
WO2022148853A1 (fr) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugués
WO2022183112A2 (fr) 2021-02-26 2022-09-01 New York University Compositions et méthodes comprenant des anticorps qui se lient à des conjugués peptidiques covalents
CN117015555A (zh) 2021-03-09 2023-11-07 豪夫迈·罗氏有限公司 Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法
KR20230156051A (ko) 2021-03-09 2023-11-13 에프. 호프만-라 로슈 아게 Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CR20240155A (es) 2021-10-14 2024-05-10 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
JP2024537096A (ja) 2021-10-14 2024-10-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート
JP2024543257A (ja) 2021-11-26 2024-11-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体およびｔｙｒｐ１特異性抗体の併用療法
CN118510535A (zh) * 2022-01-04 2024-08-16 菲洛根股份公司 包含il-12的免疫细胞因子与激酶抑制剂的组合
CN120548192A (zh) 2023-01-20 2025-08-26 豪夫迈·罗氏有限公司 免疫缀合物
WO2025202147A1 (fr) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Immunoconjugués d'interleukine-7
WO2025233304A1 (fr) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Polypeptides de variants de domaine fc-il-7 recombinants et polythérapie avec des polypeptides de liaison à l'antigène à ancrage membranaire

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CA2284079C (fr) * 1997-03-05 2009-05-12 David M. Neville Nouvelles immunotoxines et nouveaux procedes d'induction de tolerance immunitaire
WO1999029732A2 (fr) * 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Proteines de fusion heterodymeres utiles en therapie immune ciblee et a une stimulation immune generale
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
US7517526B2 (en) * 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
MX2007011407A (es) 2005-03-25 2007-11-13 Glycart Biotechnology Ag Moleculas de union a antigeno dirigidas a proteoglicano de condroitinsulfato de melanoma y con aumento de afinidad de union al receptor fc y de funcion efectora.
CA2607954A1 (fr) * 2005-05-11 2006-11-16 Philogen S.P.A. Conjugue de ciblage de medicament
US8744844B2 (en) * 2007-07-06 2014-06-03 Audience, Inc. System and method for adaptive intelligent noise suppression
CN101437847A (zh) 2006-05-08 2009-05-20 菲洛根有限公司 治疗用靶向细胞因子的抗体
US9364557B2 (en) * 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
JP5677972B2 (ja) * 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート

Also Published As

Publication number Publication date
WO2011020783A2 (fr) 2011-02-24
WO2011020783A3 (fr) 2011-04-28
AU2010285071A1 (en) 2012-02-02
PE20120630A1 (es) 2012-05-26
KR101588598B1 (ko) 2016-01-29
US20110064751A1 (en) 2011-03-17
TW201119672A (en) 2011-06-16
CA2769619A1 (fr) 2011-02-24
AR077879A1 (es) 2011-09-28
CR20120042A (es) 2012-03-22
JP5764127B2 (ja) 2015-08-12
CN102573922B (zh) 2015-08-05
CO6430436A2 (es) 2012-04-30
CA2769619C (fr) 2019-04-30
EP2467165B1 (fr) 2015-01-07
SG178443A1 (en) 2012-04-27
IL217844A0 (en) 2012-03-29
US8945571B2 (en) 2015-02-03
KR20150088328A (ko) 2015-07-31
CN102573922A (zh) 2012-07-11
JP2013502209A (ja) 2013-01-24
ZA201200767B (en) 2014-07-30
EP2467165A2 (fr) 2012-06-27
ES2534085T3 (es) 2015-04-17
RU2583876C2 (ru) 2016-05-10
KR20120053042A (ko) 2012-05-24
HK1169318A1 (zh) 2013-01-25
ECSP12011685A (es) 2012-03-30
MX2012002014A (es) 2012-06-13
RU2012110127A (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
MA33717B1 (fr) Immunoconjugués ciblés
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
WO2007042261A3 (fr) Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
WO2008076560A3 (fr) Anticorps monoclonaux humains contre le btla et procédés d'utilisation
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
MX2008009886A (es) Anticuerpos que enlazan par-2.
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2005016946A3 (fr) Complexes de platine et procedes d'utilisation
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2008108830A8 (fr) Compositions immunogènes et thérapeutiques pour streptococcus pyogenes
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2008085962A3 (fr) Méthodes de culture cellulaire destinées à la production de protéines recombinées en présence de niveaux réduits d'un ou plusieurs contaminants
WO2010072740A3 (fr) Agents de liaison ciblés dirigés contre α5β1 et leurs applications
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2006091861A8 (fr) Compositions et methodes associees au lymphome du systeme nerveux central